Not provided
Not provided
Not provided
Not provided
Not provided
PI's decision
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
The route of subcutaneous administration of drugs has become a common practice in some specialties (palliative care, geriatrics).
This is an alternative to oral, sublingual, rectal or intravenous Many drugs are used by subcutaneous route but few clinical studies evaluating the level of scientific relevance justifies their use.
The purpose of this study is to assess:
Advantages disadvantages
A practical study was conducted among 382 physicians (289 geriatricians and 93 infectious disease specialists). Among them 97.5% reported regular use of the subcutaneous route for the administration of antibiotics.
Declarative criteria pretend curb the use of this route was the lack of data Pk / Pd (61.2%); the absence of marketing authorization for the subcutaneous route (34.5%); the absence of serum assay available (2.1%).
PROTOCOL
Primary objective :
• Determine that there is no difference between the subcutaneously compared to intravenous administration in terms of dosage and serum PK / PD objectives Beta lactam in a geriatric population.
Secondary objectives:
Monitoring of antibiotic dosages:
Patient monitoring of J1-J14:
• Clinical monitoring and biological usual
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| Assessment of dermal administration of Beta-Lactams | Drug | Evaluation of Pharmacokinetic / Pharmacodynamic of dermal administration of Beta-Lactams |
| Measure | Description | Time Frame |
|---|---|---|
| Assessment of change of residual concentration of Beta-Lactam antibiotic | • Making systematic assay serum concentrations of residual antibiotics in the range of 30 min prior to reinjection H24 after starting treatment and then weekly monitoring.an | Minute 30, hour 24, Day 7. Then once a Week 2, 3, 4, 5, 6, 7, 8, 9, 10, 11 and 12 |
| Measure | Description | Time Frame |
|---|---|---|
| Assessment of patient healing (infection free) | Evaluation of healing to day 14 and day 90. The answer should be: Yes / No | Day 14 and day 90 |
Not provided
Inclusion Criteria:
Exclusion Criteria:
Not provided
Not provided
Not provided
Patients aged of >74 years old with Gram-negative bacilli and gram-positive cocci susceptible to beta-lactam
Not provided
| Name | Affiliation | Role |
|---|---|---|
| EL HELALI Najoua, MD | Fondation Hôpital Saint-Joseph | Principal Investigator |
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| Groupe Hospitalier Paris Saint Joseph | Paris | Île-de-France Region | 75014 | France |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided